Michael Ryde

Vice President, Corporate Development

MSc Business Economics, Graduate Diploma in Financing and Investments

Michael Ryde joined Pharmacosmos 1 August 2013 and Michael and today has 25 years of international experience within the pharmaceutical business. Primarily from 15 years in the Lundbeck group where he was the 1st employee both at Lundbeck’s subsidiary in Istanbul, Turkey first as the CFO and later as GM and later in China as the GM where he built the commercial team from scratch and launched Lundbeck’s first product in 2006. Later he spend two years to establish LEO Pharmaceutical’s Chinese arm of Business Development in Shanghai.

In Pharmacosmos he has had different roles starting with having commercial responsibility for the Human Iron business unit with responsibility for subsidiaries in UK, Nordics and Germany including partner management where he established several important partnerships among others with Pfizer for Canada, Australia and Brazil. Latest in 2018 he took charge of the US market first searching for a partner for Monoferric which developed into the role of US CEO for Pharmacosmos’ own, new US subsidiary and responsible for building out the US organization to 110 employees with a successful launch on Oct/1 2020 in the middle of covid lock-down.

He says “I am proud of having been part of the tremendous journey that Pharmacosmos has been on during the last ten years where Pharmacosmos today has a significant presence with own subsidiary in the two biggest pharmaceutical markets in the world, US and China as well as in Germany, UK and the Nordics. With this presence and our ambitions to supplement the steady organic growth across all markets with growth through business development which I am now in charge of through in-licensing or M&A, I see a bright future for Pharmacosmos where we are just at the beginning of a long growth journey. Really exciting to be part of”


Please identify if you are a: